1. Home
  2. MUA vs TECX Comparison

MUA vs TECX Comparison

Compare MUA & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniAssets Fund Inc

MUA

Blackrock MuniAssets Fund Inc

HOLD

Current Price

$10.89

Market Cap

407.5M

Sector

Finance

ML Signal

HOLD

Logo Tectonic Therapeutic Inc. Common Stock

TECX

Tectonic Therapeutic Inc. Common Stock

HOLD

Current Price

$20.16

Market Cap

359.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUA
TECX
Founded
1993
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
407.5M
359.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
MUA
TECX
Price
$10.89
$20.16
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$81.20
AVG Volume (30 Days)
92.6K
363.4K
Earning Date
01-01-0001
11-06-2025
Dividend Yield
4.84%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.61
$13.70
52 Week High
$11.43
$61.07

Technical Indicators

Market Signals
Indicator
MUA
TECX
Relative Strength Index (RSI) 54.91 54.59
Support Level $10.56 $18.60
Resistance Level $10.69 $21.50
Average True Range (ATR) 0.16 1.68
MACD 0.04 0.04
Stochastic Oscillator 71.87 57.51

Price Performance

Historical Comparison
MUA
TECX

About MUA Blackrock MuniAssets Fund Inc

Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations. The Fund invests more of its total assets in municipal bonds.

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: